company background image
EDIT logo

Editas Medicine NasdaqGS:EDIT Stock Report

Last Price

US$5.11

Market Cap

US$414.5m

7D

1.0%

1Y

-36.7%

Updated

21 Jun, 2024

Data

Company Financials +

Editas Medicine, Inc.

NasdaqGS:EDIT Stock Report

Market Cap: US$414.5m

EDIT Stock Overview

A clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.

EDIT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Editas Medicine, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Editas Medicine
Historical stock prices
Current Share PriceUS$5.11
52 Week HighUS$11.69
52 Week LowUS$4.82
Beta2.05
11 Month Change-15.12%
3 Month Change-31.59%
1 Year Change-36.68%
33 Year Change-87.80%
5 Year Change-79.35%
Change since IPO-71.92%

Recent News & Updates

Recent updates

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

May 12
Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Apr 23
The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Mar 09
Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Feb 28

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Dec 15
New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

May 10
Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Jan 19
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Oct 18

Editas Medicine started at neutral at BofA due to competition in gene editing programs

Sep 29

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Sep 13
We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies

Aug 23

Editas Medicine Q2 2022 Earnings Preview

Aug 02

Baisong Mei joins Editas Medicine as Chief Medical Officer

Jul 18

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Jun 12
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Editas: Tackling Rare Eye Disease With Use Of Crispr Technology

Jun 06

Editas: The Unforeseen Detrimental Effect Of Patent Win

Mar 25

Editas: CRISPR Gene Editing Biotech With Promising Future

Mar 15

Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Feb 25
Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price Recently

Dec 28

Editas - The Introvert Crispr Biotech Too Shy To Flex Its Muscles

Dec 15

Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Nov 17
Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Editas: Data Was Eagerly Anticipated But Failed To Impress

Nov 03

Shareholder Returns

EDITUS BiotechsUS Market
7D1.0%-0.009%0.5%
1Y-36.7%9.8%23.9%

Return vs Industry: EDIT underperformed the US Biotechs industry which returned 9.8% over the past year.

Return vs Market: EDIT underperformed the US Market which returned 23.9% over the past year.

Price Volatility

Is EDIT's price volatile compared to industry and market?
EDIT volatility
EDIT Average Weekly Movement9.5%
Biotechs Industry Average Movement10.5%
Market Average Movement5.7%
10% most volatile stocks in US Market15.4%
10% least volatile stocks in US Market2.8%

Stable Share Price: EDIT's share price has been volatile over the past 3 months.

Volatility Over Time: EDIT's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013265Gilmore O’Neillwww.editasmedicine.com

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.

Editas Medicine, Inc. Fundamentals Summary

How do Editas Medicine's earnings and revenue compare to its market cap?
EDIT fundamental statistics
Market capUS$414.48m
Earnings (TTM)-US$166.13m
Revenue (TTM)US$69.41m

6.1x

P/S Ratio

-2.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EDIT income statement (TTM)
RevenueUS$69.41m
Cost of RevenueUS$188.63m
Gross Profit-US$119.23m
Other ExpensesUS$46.91m
Earnings-US$166.13m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.02
Gross Margin-171.78%
Net Profit Margin-239.36%
Debt/Equity Ratio0%

How did EDIT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.